<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701698</url>
  </required_header>
  <id_info>
    <org_study_id>SHSYXY-Ruxo-GVHD-2018001</org_study_id>
    <nct_id>NCT03701698</nct_id>
  </id_info>
  <brief_title>Ruxolitinib and Steroid as First Line Therapy for Acute GVHD</brief_title>
  <official_title>Ruxolitinib and Methylprednisolone as First Line Therapy for Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with&#xD;
      methylprednisolone as first line therapy in patients with Grades II to IV acute&#xD;
      graft-versus-host disease (GVHD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment:&#xD;
&#xD;
      Once patients are diagnosed with grade II~IV acute GVHD, the combination therapy should be&#xD;
      initiated as soon as possible.&#xD;
&#xD;
        1. Methylprednisolone: 2mg/kg/d, iv or iv gtt, in two or three divided doses. Taper steroid&#xD;
           every one or two weeks according to patient's response.&#xD;
&#xD;
        2. Ruxolitinib 5~10mg bid po for at least 28 days. If patient's ANC&lt;0.5×10e9/L or PLT&lt;&#xD;
           20×10e9/L, cease ruxolitinib until recovery of ANC higher than 0.5×10e9/L or PLT higher&#xD;
           than 20×10e9/L.&#xD;
&#xD;
      Indication for stopping Ruxolitinib treatment:&#xD;
&#xD;
        1. No response after ruxolitinib treatment for 28 days.&#xD;
&#xD;
        2. Develop life-threatening complication.&#xD;
&#xD;
        3. ANC&lt;0.5×10e9/L or PLT&lt; 20×10e9/L.&#xD;
&#xD;
      Indication for second line acute GVHD treatment:&#xD;
&#xD;
        1. deterioration of acute GVHD in 3 days&#xD;
&#xD;
        2. no response after 7 days&#xD;
&#xD;
        3. no complete remission after 2 weeks.&#xD;
&#xD;
      Suggestions of second line therapy:&#xD;
&#xD;
      Basiliximab 20mg, d1, d4, d8.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>overall response rate of acute GVHD treatment, including complete response rate and partial response rate after combination therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to response</measure>
    <time_frame>28 days after treatment</time_frame>
    <description>days from beginning to the first day of maximum response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reactivation rate of cytomegalovirus</measure>
    <time_frame>100 days within transplant</time_frame>
    <description>reactivation rate of cytomegalovirus infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 year incidence of chronic GVHD</measure>
    <time_frame>1 year within transplant</time_frame>
    <description>incidence of chronic GVHD 1 year after transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute GVHD</condition>
  <arm_group>
    <arm_group_label>combination therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>There is only 1 arm. Combination therapy arm includes ruxolitinib and methylprednisolone.&#xD;
Methylprednisolone: 2mg/kg/d , iv or iv gtt for at least 1 week, then taper according to the clinical response.&#xD;
Ruxolitinib oral tablet, 5~10mg bid orally, for at least 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib Oral Tablet</intervention_name>
    <description>Ruxolitinib Oral Tablet （Jakafi）, 5~10mg bid po for at least 28 days.</description>
    <arm_group_label>combination therapy</arm_group_label>
    <other_name>Jakafi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone: 2mg/kg/d , iv or iv gtt, for at least 1 week, then taper accordingly.</description>
    <arm_group_label>combination therapy</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. diagnosed with hematological diseases.&#xD;
&#xD;
          2. recipients of allogeneic peripheral blood stem cell transplantation.&#xD;
&#xD;
          3. new onset of grade II~IV acute graft versus host disease within 100 days&#xD;
             post-transplantation.&#xD;
&#xD;
        exclusion criteria:&#xD;
&#xD;
          1. recipients of second allogeneic stem cell transplant.&#xD;
&#xD;
          2. acute GVHD induced by donor lymphocyte infusion, interferon.&#xD;
&#xD;
          3. received treatment other than steroid before enrollment.&#xD;
&#xD;
          4. overlap GVHD syndrome.&#xD;
&#xD;
          5. pregnant or breast-feeding women.&#xD;
&#xD;
          6. absolute neutrophil count (ANC) &lt;0.5×10e9/L or platelet count (PLT) &lt; 20×10e9/L&#xD;
&#xD;
          7. non-GVHD related liver dysfunction: glutamic pyruvic transaminase&gt;= 4 times of upper&#xD;
             normal limit, direct bilirubin &gt;= 4 times of upper normal limit&#xD;
&#xD;
          8. renal dysfunction: creatinine clearance &lt; 15 mL/min or glomerular filtration rate&lt; 15&#xD;
             mL/min&#xD;
&#xD;
          9. uncontrolled infection&#xD;
&#xD;
         10. human immunodeficiency virus infection&#xD;
&#xD;
         11. active hepatitis b virus, hepatitis C virus infection and need antivirus treatment.&#xD;
&#xD;
         12. relapse of primary malignant hematological diseases, or graft rejection.&#xD;
&#xD;
         13. allergic history to Janus kinase inhibitors.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xianmin Song, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liping Wan, M.D.</last_name>
    <phone>86-21-37798987</phone>
    <email>lipingwan@sjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jieling Jiang, M.D.</last_name>
    <phone>86-21-37798987</phone>
    <email>Jiangjieling66@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>October 12, 2018</last_update_submitted>
  <last_update_submitted_qc>October 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xianmin Song, MD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

